By ensuring human relevance first, our expertise in “brain mapping” reveals or reinforces appropriate scientific avenues for understanding CNS disease.
We assess for translational relevance, rank drug targets for efficacy, mitigate side effect concerns, and uncover alternative applications for well characterized compounds (repurposing).
Using comprehensive and precise brain data sets, we furnish additional lines of evidence needed for reproducibility, translational relevance, and corroboration in support of multiple applications (NIH, FDA, EPA, publication).
We’ve industrialized brain research across several disciplines. Let us help you mitigate various scientific, technical, and operational challenges to develop your most effective scientific strategy.
Current Research Goal
One clear reason CNS drugs have mixed success arises from the difficulty in controlling for genetic and anatomic variability across species, explaining in part why success in animal models doesn’t translate to humans. Untested assumptions carry considerable translational risks, which dilute the research endeavor and require additional time and money to resolve (e.g. waiting for clinical trials to reveal variability). We apply efficient cross-disciplinary expertise much earlier in the drug development process to help guide researchers to the most human relevant questions, thereby focusing critical resources and accelerating the development of therapies for patients.
Promising results in animal models